Copyright Reports & Markets. All rights reserved.

Global Neonatal Genetic Disease Diagnosis Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Neonatal Genetic Disease Diagnosis by Type
    • 1.3.1 Overview: Global Neonatal Genetic Disease Diagnosis Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Neonatal Genetic Disease Diagnosis Consumption Value Market Share by Type in 2025
    • 1.3.3 Targeted Gene Panel Testing
    • 1.3.4 Whole Exome Sequencing
    • 1.3.5 Whole Genome Sequencing
  • 1.4 Classification of Neonatal Genetic Disease Diagnosis by Disease Coverage
    • 1.4.1 Overview: Global Neonatal Genetic Disease Diagnosis Market Size by Disease Coverage: 2021 Versus 2025 Versus 2032
    • 1.4.2 Global Neonatal Genetic Disease Diagnosis Consumption Value Market Share by Disease Coverage in 2025
    • 1.4.3 Inherited Metabolic Disease Diagnosis
    • 1.4.4 Primary Immunodeficiency Diagnosis
    • 1.4.5 Neuromuscular and Developmental Disorder Diagnosis
  • 1.5 Classification of Neonatal Genetic Disease Diagnosis by Turnaround Time
    • 1.5.1 Overview: Global Neonatal Genetic Disease Diagnosis Market Size by Turnaround Time: 2021 Versus 2025 Versus 2032
    • 1.5.2 Global Neonatal Genetic Disease Diagnosis Consumption Value Market Share by Turnaround Time in 2025
    • 1.5.3 Rapid Diagnosis（≤7 days）
    • 1.5.4 Standard Diagnosis（8–21 days）
    • 1.5.5 Extended Diagnosis（＞21 days）
  • 1.6 Global Neonatal Genetic Disease Diagnosis Market by Application
    • 1.6.1 Overview: Global Neonatal Genetic Disease Diagnosis Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.6.2 Hospitals
    • 1.6.3 Third-Party Clinical Laboratories
    • 1.6.4 Public Health Screening Centers
    • 1.6.5 Other
  • 1.7 Global Neonatal Genetic Disease Diagnosis Market Size & Forecast
  • 1.8 Global Neonatal Genetic Disease Diagnosis Market Size and Forecast by Region
    • 1.8.1 Global Neonatal Genetic Disease Diagnosis Market Size by Region: 2021 VS 2025 VS 2032
    • 1.8.2 Global Neonatal Genetic Disease Diagnosis Market Size by Region, (2021-2032)
    • 1.8.3 North America Neonatal Genetic Disease Diagnosis Market Size and Prospect (2021-2032)
    • 1.8.4 Europe Neonatal Genetic Disease Diagnosis Market Size and Prospect (2021-2032)
    • 1.8.5 Asia-Pacific Neonatal Genetic Disease Diagnosis Market Size and Prospect (2021-2032)
    • 1.8.6 South America Neonatal Genetic Disease Diagnosis Market Size and Prospect (2021-2032)
    • 1.8.7 Middle East & Africa Neonatal Genetic Disease Diagnosis Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 GeneDx
    • 2.1.1 GeneDx Details
    • 2.1.2 GeneDx Major Business
    • 2.1.3 GeneDx Neonatal Genetic Disease Diagnosis Product and Solutions
    • 2.1.4 GeneDx Neonatal Genetic Disease Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 GeneDx Recent Developments and Future Plans
  • 2.2 Revvity
    • 2.2.1 Revvity Details
    • 2.2.2 Revvity Major Business
    • 2.2.3 Revvity Neonatal Genetic Disease Diagnosis Product and Solutions
    • 2.2.4 Revvity Neonatal Genetic Disease Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Revvity Recent Developments and Future Plans
  • 2.3 Labcorp
    • 2.3.1 Labcorp Details
    • 2.3.2 Labcorp Major Business
    • 2.3.3 Labcorp Neonatal Genetic Disease Diagnosis Product and Solutions
    • 2.3.4 Labcorp Neonatal Genetic Disease Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Labcorp Recent Developments and Future Plans
  • 2.4 Quest Diagnostics
    • 2.4.1 Quest Diagnostics Details
    • 2.4.2 Quest Diagnostics Major Business
    • 2.4.3 Quest Diagnostics Neonatal Genetic Disease Diagnosis Product and Solutions
    • 2.4.4 Quest Diagnostics Neonatal Genetic Disease Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Quest Diagnostics Recent Developments and Future Plans
  • 2.5 Centogene
    • 2.5.1 Centogene Details
    • 2.5.2 Centogene Major Business
    • 2.5.3 Centogene Neonatal Genetic Disease Diagnosis Product and Solutions
    • 2.5.4 Centogene Neonatal Genetic Disease Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Centogene Recent Developments and Future Plans
  • 2.6 Baylor Genetics
    • 2.6.1 Baylor Genetics Details
    • 2.6.2 Baylor Genetics Major Business
    • 2.6.3 Baylor Genetics Neonatal Genetic Disease Diagnosis Product and Solutions
    • 2.6.4 Baylor Genetics Neonatal Genetic Disease Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Baylor Genetics Recent Developments and Future Plans
  • 2.7 Fulgent Genetics
    • 2.7.1 Fulgent Genetics Details
    • 2.7.2 Fulgent Genetics Major Business
    • 2.7.3 Fulgent Genetics Neonatal Genetic Disease Diagnosis Product and Solutions
    • 2.7.4 Fulgent Genetics Neonatal Genetic Disease Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Fulgent Genetics Recent Developments and Future Plans
  • 2.8 ARUP Laboratories
    • 2.8.1 ARUP Laboratories Details
    • 2.8.2 ARUP Laboratories Major Business
    • 2.8.3 ARUP Laboratories Neonatal Genetic Disease Diagnosis Product and Solutions
    • 2.8.4 ARUP Laboratories Neonatal Genetic Disease Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 ARUP Laboratories Recent Developments and Future Plans
  • 2.9 BGI Genomics
    • 2.9.1 BGI Genomics Details
    • 2.9.2 BGI Genomics Major Business
    • 2.9.3 BGI Genomics Neonatal Genetic Disease Diagnosis Product and Solutions
    • 2.9.4 BGI Genomics Neonatal Genetic Disease Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 BGI Genomics Recent Developments and Future Plans
  • 2.10 Berry Genomics
    • 2.10.1 Berry Genomics Details
    • 2.10.2 Berry Genomics Major Business
    • 2.10.3 Berry Genomics Neonatal Genetic Disease Diagnosis Product and Solutions
    • 2.10.4 Berry Genomics Neonatal Genetic Disease Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Berry Genomics Recent Developments and Future Plans
  • 2.11 Annoroad Gene Technology
    • 2.11.1 Annoroad Gene Technology Details
    • 2.11.2 Annoroad Gene Technology Major Business
    • 2.11.3 Annoroad Gene Technology Neonatal Genetic Disease Diagnosis Product and Solutions
    • 2.11.4 Annoroad Gene Technology Neonatal Genetic Disease Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Annoroad Gene Technology Recent Developments and Future Plans
  • 2.12 CapitalBio Technology
    • 2.12.1 CapitalBio Technology Details
    • 2.12.2 CapitalBio Technology Major Business
    • 2.12.3 CapitalBio Technology Neonatal Genetic Disease Diagnosis Product and Solutions
    • 2.12.4 CapitalBio Technology Neonatal Genetic Disease Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 CapitalBio Technology Recent Developments and Future Plans
  • 2.13 KingMed Diagnostics
    • 2.13.1 KingMed Diagnostics Details
    • 2.13.2 KingMed Diagnostics Major Business
    • 2.13.3 KingMed Diagnostics Neonatal Genetic Disease Diagnosis Product and Solutions
    • 2.13.4 KingMed Diagnostics Neonatal Genetic Disease Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 KingMed Diagnostics Recent Developments and Future Plans
  • 2.14 Novogene
    • 2.14.1 Novogene Details
    • 2.14.2 Novogene Major Business
    • 2.14.3 Novogene Neonatal Genetic Disease Diagnosis Product and Solutions
    • 2.14.4 Novogene Neonatal Genetic Disease Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 Novogene Recent Developments and Future Plans
  • 2.15 Da An Gene
    • 2.15.1 Da An Gene Details
    • 2.15.2 Da An Gene Major Business
    • 2.15.3 Da An Gene Neonatal Genetic Disease Diagnosis Product and Solutions
    • 2.15.4 Da An Gene Neonatal Genetic Disease Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 Da An Gene Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Neonatal Genetic Disease Diagnosis Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Neonatal Genetic Disease Diagnosis by Company Revenue
    • 3.2.2 Top 3 Neonatal Genetic Disease Diagnosis Players Market Share in 2025
    • 3.2.3 Top 6 Neonatal Genetic Disease Diagnosis Players Market Share in 2025
  • 3.3 Neonatal Genetic Disease Diagnosis Market: Overall Company Footprint Analysis
    • 3.3.1 Neonatal Genetic Disease Diagnosis Market: Region Footprint
    • 3.3.2 Neonatal Genetic Disease Diagnosis Market: Company Product Type Footprint
    • 3.3.3 Neonatal Genetic Disease Diagnosis Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Neonatal Genetic Disease Diagnosis Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Neonatal Genetic Disease Diagnosis Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Neonatal Genetic Disease Diagnosis Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Neonatal Genetic Disease Diagnosis Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Neonatal Genetic Disease Diagnosis Consumption Value by Type (2021-2032)
  • 6.2 North America Neonatal Genetic Disease Diagnosis Market Size by Application (2021-2032)
  • 6.3 North America Neonatal Genetic Disease Diagnosis Market Size by Country
    • 6.3.1 North America Neonatal Genetic Disease Diagnosis Consumption Value by Country (2021-2032)
    • 6.3.2 United States Neonatal Genetic Disease Diagnosis Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Neonatal Genetic Disease Diagnosis Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Neonatal Genetic Disease Diagnosis Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Neonatal Genetic Disease Diagnosis Consumption Value by Type (2021-2032)
  • 7.2 Europe Neonatal Genetic Disease Diagnosis Consumption Value by Application (2021-2032)
  • 7.3 Europe Neonatal Genetic Disease Diagnosis Market Size by Country
    • 7.3.1 Europe Neonatal Genetic Disease Diagnosis Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Neonatal Genetic Disease Diagnosis Market Size and Forecast (2021-2032)
    • 7.3.3 France Neonatal Genetic Disease Diagnosis Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Neonatal Genetic Disease Diagnosis Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Neonatal Genetic Disease Diagnosis Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Neonatal Genetic Disease Diagnosis Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Neonatal Genetic Disease Diagnosis Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Neonatal Genetic Disease Diagnosis Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Neonatal Genetic Disease Diagnosis Market Size by Region
    • 8.3.1 Asia-Pacific Neonatal Genetic Disease Diagnosis Consumption Value by Region (2021-2032)
    • 8.3.2 China Neonatal Genetic Disease Diagnosis Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Neonatal Genetic Disease Diagnosis Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Neonatal Genetic Disease Diagnosis Market Size and Forecast (2021-2032)
    • 8.3.5 India Neonatal Genetic Disease Diagnosis Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Neonatal Genetic Disease Diagnosis Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Neonatal Genetic Disease Diagnosis Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Neonatal Genetic Disease Diagnosis Consumption Value by Type (2021-2032)
  • 9.2 South America Neonatal Genetic Disease Diagnosis Consumption Value by Application (2021-2032)
  • 9.3 South America Neonatal Genetic Disease Diagnosis Market Size by Country
    • 9.3.1 South America Neonatal Genetic Disease Diagnosis Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Neonatal Genetic Disease Diagnosis Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Neonatal Genetic Disease Diagnosis Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Neonatal Genetic Disease Diagnosis Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Neonatal Genetic Disease Diagnosis Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Neonatal Genetic Disease Diagnosis Market Size by Country
    • 10.3.1 Middle East & Africa Neonatal Genetic Disease Diagnosis Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Neonatal Genetic Disease Diagnosis Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Neonatal Genetic Disease Diagnosis Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Neonatal Genetic Disease Diagnosis Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Neonatal Genetic Disease Diagnosis Market Drivers
  • 11.2 Neonatal Genetic Disease Diagnosis Market Restraints
  • 11.3 Neonatal Genetic Disease Diagnosis Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Neonatal Genetic Disease Diagnosis Industry Chain
  • 12.2 Neonatal Genetic Disease Diagnosis Upstream Analysis
  • 12.3 Neonatal Genetic Disease Diagnosis Midstream Analysis
  • 12.4 Neonatal Genetic Disease Diagnosis Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Neonatal Genetic Disease Diagnosis market size was valued at US$ 2017 million in 2025 and is forecast to a readjusted size of US$ 3844 million by 2032 with a CAGR of 9.6% during review period.
    In 2025, global Neonatal Genetic Disease Diagnosis production reached approximately 10.59 million tests, with an average global market price of around USD 185 per test.
    The gross profit margin of major companies in the industry is between 32.45%–55.36%.
    In 2025, the global production capacity of Neonatal Genetic Disease Diagnosis was approximately 13.94 million tests.
    Neonatal Genetic Disease Diagnosis refers to genetic testing and related diagnostic services used to identify inherited or congenital diseases in newborns. It may involve targeted panels, sequencing, copy number analysis, biochemical confirmation and clinical interpretation based on blood spots, blood samples or other neonatal specimens. The product scope covers diagnostic test kits, laboratory-developed testing services, sequencing-based screening and confirmatory genetic diagnosis for newborn diseases. It excludes prenatal testing, adult genetic testing, routine biochemical newborn screening without genetic analysis and general pediatric diagnostics unrelated to inherited disease.
    The industry chain includes sample collection materials, nucleic acid extraction reagents, sequencing reagents, assay kits, bioinformatics tools, laboratory instruments, databases and quality control materials. Midstream activities include sample processing, genetic testing, data analysis, variant interpretation, report generation and clinical consultation. Downstream users include hospitals, newborn screening centers, clinical laboratories, pediatric departments, public health programs and families. Demand is driven by early disease detection, declining sequencing costs, expanded screening panels, rare disease awareness and healthcare policies supporting early intervention.
    Improved national prenatal and newborn healthcare system plus birth defect prevention policies expand neonatal genetic disease diagnosis market. Early screening achieves timely intervention to reduce congenital disease incidence. High-throughput testing technology continuously improves detection coverage and accuracy.
    This report is a detailed and comprehensive analysis for global Neonatal Genetic Disease Diagnosis market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Neonatal Genetic Disease Diagnosis market size and forecasts, in consumption value ($ Million), 2021-2032
    Global Neonatal Genetic Disease Diagnosis market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global Neonatal Genetic Disease Diagnosis market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global Neonatal Genetic Disease Diagnosis market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Neonatal Genetic Disease Diagnosis
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Neonatal Genetic Disease Diagnosis market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GeneDx, Revvity, Labcorp, Quest Diagnostics, Centogene, Baylor Genetics, Fulgent Genetics, ARUP Laboratories, BGI Genomics, Berry Genomics, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Neonatal Genetic Disease Diagnosis market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Targeted Gene Panel Testing
    Whole Exome Sequencing
    Whole Genome Sequencing
    Market segment by Disease Coverage
    Inherited Metabolic Disease Diagnosis
    Primary Immunodeficiency Diagnosis
    Neuromuscular and Developmental Disorder Diagnosis
    Market segment by Turnaround Time
    Rapid Diagnosis（≤7 days）
    Standard Diagnosis（8–21 days）
    Extended Diagnosis（＞21 days）
    Market segment by Application
    Hospitals
    Third-Party Clinical Laboratories
    Public Health Screening Centers
    Other
    Market segment by players, this report covers
    GeneDx
    Revvity
    Labcorp
    Quest Diagnostics
    Centogene
    Baylor Genetics
    Fulgent Genetics
    ARUP Laboratories
    BGI Genomics
    Berry Genomics
    Annoroad Gene Technology
    CapitalBio Technology
    KingMed Diagnostics
    Novogene
    Da An Gene
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Neonatal Genetic Disease Diagnosis product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Neonatal Genetic Disease Diagnosis, with revenue, gross margin, and global market share of Neonatal Genetic Disease Diagnosis from 2021 to 2026.
    Chapter 3, the Neonatal Genetic Disease Diagnosis competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Neonatal Genetic Disease Diagnosis market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Neonatal Genetic Disease Diagnosis.
    Chapter 13, to describe Neonatal Genetic Disease Diagnosis research findings and conclusion.

    Buy now